Literature DB >> 24275930

Multiple sclerosis: Oral laquinimod for MS--bringing the brain into focus.

Wolfgang Brück1, Timothy Vollmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24275930     DOI： 10.1038/nrneurol.2013.234

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

1.  Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Authors:  Giancarlo Comi; Douglas Jeffery; Ludwig Kappos; Xavier Montalban; Alexey Boyko; Maria A Rocca; Massimo Filippi
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

2.  Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.

Authors:  Massimo Filippi; Maria A Rocca; Elisabetta Pagani; Nicola De Stefano; Douglas Jeffery; Ludwig Kappos; Xavier Montalban; Alexei N Boyko; Giancarlo Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-12       Impact factor: 10.154

Review 3.  Pathology and disease mechanisms in different stages of multiple sclerosis.

Authors:  Hans Lassmann
Journal:  J Neurol Sci       Date:  2013-06-02       Impact factor: 3.181

Review 4.  Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Wolfgang Brück; Scott S Zamvil
Journal:  Expert Rev Clin Pharmacol       Date:  2012-05       Impact factor: 5.045

Review 5.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

6.  Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

Authors:  Valérie Jolivel; Felix Luessi; Joumana Masri; Stefan H P Kraus; Mario Hubo; Laura Poisa-Beiro; Sabrina Klebow; Magdalena Paterka; Nir Yogev; Hayrettin Tumani; Roberto Furlan; Volker Siffrin; Helmut Jonuleit; Frauke Zipp; Ari Waisman
Journal:  Brain       Date:  2013-03-20       Impact factor: 13.501

7.  Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.

Authors:  Wolfgang Brück; Ramona Pförtner; Trinh Pham; Jingya Zhang; Liat Hayardeny; Victor Piryatinsky; Uwe-Karsten Hanisch; Tommy Regen; Denise van Rossum; Lars Brakelmann; Karin Hagemeier; Tanja Kuhlmann; Christine Stadelmann; Gareth R John; Nadine Kramann; Christiane Wegner
Journal:  Acta Neuropathol       Date:  2012-07-06       Impact factor: 17.088

8.  Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

Authors:  Ulf Schulze-Topphoff; Aparna Shetty; Michel Varrin-Doyer; Nicolas Molnarfi; Sharon A Sagan; Raymond A Sobel; Patricia A Nelson; Scott S Zamvil
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240
  8 in total
  3 in total

Review 1.  Control of immune-mediated pathology via the aryl hydrocarbon receptor.

Authors:  Michael A Wheeler; Veit Rothhammer; Francisco J Quintana
Journal:  J Biol Chem       Date:  2017-06-14       Impact factor: 5.157

Review 2.  Role and therapeutic value of dendritic cells in central nervous system autoimmunity.

Authors:  F J Quintana; A Yeste; I D Mascanfroni
Journal:  Cell Death Differ       Date:  2014-08-29       Impact factor: 15.828

3.  Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.

Authors:  Manoj Kumar Mishra; Janet Wang; Michael B Keough; Yan Fan; Claudia Silva; Scott Sloka; Liat Hayardeny; Wolfgang Brück; V Wee Yong
Journal:  Ann Clin Transl Neurol       Date:  2014-05-26       Impact factor: 4.511
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.